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Abstract: Glimepiride is an antidiabetic drug which is one of the third generation sulfonylureas.
It belongs to class II, according to the BCS (Biopharmaceutical Classification System), which is
characterized by low solubility and high permeability. The aim of this work was to formulate
glimepiride as solid dispersion using water-soluble carriers to enhance its aqueous solubility and
thus enhance its bioavailability. Nine formulations of glimepiride solid dispersion were prepared
by a solvent evaporation technique using three different carriers (mannitol, polyethylene glycol
6000, and β-cyclodextrin) with three different drug carrier ratio (1:1, 1:3, and 1:6). Formulation
variables were optimized using 32 full factorial design. The prepared formulations were evaluated
for production yield, drug content, micromeritic properties, thermal analysis, in-vitro release, and
in-vivo hypoglycemic effect. All prepared formulations showed high production yield ranged
from 98.4 ± 2.8 to 99.8 ± 2.2% and high drug content in the range of 97.2 ± 3.2 to 99.6 ± 2.1%.
The micromeritic properties revealed that all prepared glimepiride formulations showed good
flowability. The differential scanning calorimetry study revealed the presence of the drug in the more
soluble amorphous form. In accordance with the results of in vitro release study, it was found that
the solubility of glimepiride was increased by increasing the drug carrier ratio, compared with the
pure form of the drug. It was found that F9 showed a high and rapid reduction in blood glucose
levels in diabetic rats, which indicated the success of a solid dispersion technique in improving the
solubility and hence the bioavailability of glimepiride.
Keywords: solid dispersion; solvent evaporation; solubility enhancer; polyethylene glycol (PEG);
β-cyclodextrin; mannitol

1. Introduction
Type II diabetes mellitus, previously known as noninsulin-dependent diabetes or adult-onset
diabetes, accounts for 90–95% of all diabetes cases [1]. It encompasses individuals who have relative
insulin deficiency and have peripheral insulin resistance [2]. At least initially, and often throughout
their lifetime, these individuals may not need insulin treatment to survive. Indeed, diabetes requires
continuous medical care with multifactorial risk-reduction strategies beyond glycemic control [3].
Sci. Pharm. 2020, 88, 52; doi:10.3390/scipharm88040052
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Since 80% of people with diabetes are treated with oral hypoglycemic agents, it is very important
to establish appropriate guidelines for their selection, formulation, and use [4]. An oral antidiabetic
drug is a first-line treatment for Type II diabetes [5]. Glimepiride (GM) is one of the third generation
sulfonylurea oral antidiabetic drugs used in the treatment of type II diabetes mellitus [6]. GM is
characterized by high hypoglycemic efficacy and low systemic toxicity [7]. It belongs to class II drugs,
according to the Biopharmaceutical Classification System (BCS), characterized by low solubility and
high permeability [8]. The poor water solubility of GM leads to difficultly in preparation for good oral
pharmaceutical preparation, poor dissolution profile, and low bioavailability [9]. The rate and extent
of oral absorption of such poor water-soluble drugs are controlled by the dissolution rate in the fluids
of the gastrointestinal tract [10]. So, the present study aimed to enhance the water solubility of GM to
increase the dissolution rate and hence the oral bioavailability. A lot of techniques are available to
enhance the solubility of poorly water-soluble drugs [11]. These techniques include using prodrug [12],
salt formation [13], crystal engineering of the drug [14], solid dispersion method using water-soluble
polymer [15,16]. Solid dispersion is a well-established technique used in enhancing the aqueous
solubility of poorly water-soluble drugs [17]. In this technique, the poorly water-soluble drugs are
dispersed though out a water-soluble carrier such as urea, mannitol, polyethylene glycol, polyvinyl
pyrrolidone, β-cyclodextrin, lactose, and hydroxyl propyl methyl cellulose [18]. The process of solid
dispersion is done by melting, solvent evaporation, and spray drying methods [8,19]. Wagh et al.
prepared glimepiride solid dispersion by kneading method using both poloxamer 188 and poloxamer
407 as a water-soluble polymer for improving the water solubility of GM [8]. Ning et al. prepared
solid dispersion of GM by solvent evaporation technique using PVPk30 as a water-soluble carrier for
enhancement of water solubility [9]. Mehta et al. prepared GM solid dispersion by solvent evaporation
method using PREG6000 as a water-soluble carrier for improving oral absorption and hence the
antidiabetic effect [20].
The aim of this study is to formulate GM in the form of solid dispersion to enhance its solubility
and hence the dissolution rate and its oral bioavailability. The formulations of GM solid dispersion were
prepared by the solvent evaporation technique using three different carriers (mannitol, polyethylene
glycol (PEG) 6000, and β-cyclodextrin) with three different drug carrier ratio (1:1, 1:3, and 1:6) and
optimized using 32 full factorial design. The selection of mannitol, PEG 6000, and beta-cyclodextrin
was based on the results of previously published papers, which concluded that those carriers were
effective for the enhancement of solubility of poorly water-soluble drugs. The prepared formulation
was evaluated for the production yield, drug content, micromeritic properties, thermal analysis, and
in-vitro release study to select the optimized formulation. The optimized formulation was evaluated
in streptozotocin-diabetic mice for its hypoglycemic effect in comparison with the free form of GM.
2. Materials and Methods
2.1. The Materials
GM was obtained from Tabuk pharmaceutical Company (Tabuk, Saudi Arabia); PEG 6000 and
β-cyclodextrin were purchased from Oxford Laboratory Chemicals (Mumbai, India). Mannitol and
methanol were purchased from Sigma Aldrich Sigma Chemical Co (St. Louis, MO, USA. Other
chemicals were of analytical grade and were used without further modifications. Double-distilled
deionized water was used for the experiments.
2.2. The Methods
2.2.1. The Experimental Design
A (32 ) full factorial design was used to formulate nine formulations of GM solid dispersion (F1–F9)
using the design expert software program, version 12. The factorial design was employed to study
the effect of two independent variables (X1 , and X2 ), each with three levels (+1, 0, and −1) on the
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dependent variable (Y1 ). The independent variables were the type of carrier (X1 ), drug carrier ratio
(X2 ), while the dependent variable was the percentage of drug released after 1 hr (Y1 ). The dependent
and independent variables are represented in Table 1.
Table 1. Dependent and independent formulation variables and their levels according to 32 factorial
design. PEG: polyethylene glycol.
Independent Factors

Low (−1)

X1 = Type of carrier
X2 = Drug: Carrier ratio
Dependent Variables
Y1 = The drug release (%)

Mannitol
1:1

Medium (0)
PEG 6000
1:3
Goal
Maximize

High (1)
β-Cyclodextrin
1:6

2.2.2. The Preparation of GM Solid Dispersion
The solid dispersion of GM was prepared by a solvent evaporation technique [21]. The weighed
amounts of GM and the carriers were dissolved in 10 mL of methanol in a round-bottomed flask.
The solvent was allowed to evaporate using a Heidolph rotavap (Schwabach, Germany), rotated at
100 rpm at 25 ± 1 ◦ C under 600 mmHg pressure until it is completely dry. Methanol was evaporated,
leaving the solid dispersion of GM on the wall of a round-bottomed flask [22]. The prepared GM
solid dispersions were collected and further dried in an oven at 40 ◦ C for 24 h, then ground and
kept in a desiccator over silica at 60% relative humidity at room temperature for further studies. The
composition of the nine formulations of GM solid dispersion is represented in Table 2.
Table 2. Glimepiride solid dispersion formulations according to 32 factorial design.
Formulation No.

Variable X1

Variable X2

F1
F2
F3
F4
F5
F6
F7
F8
F9

−1
−1
−1
0
0
0
1
1
1

−1
0
1
−1
0
1
−1
0
1

Where +1 is the higher level, −1 is the lower level, and 0 is the medium level for the independent variables.

2.2.3. The Production Yield of GM Solid Dispersion
The production yield of all prepared formulations of GM solid dispersion was estimated by the
following equation [23]:
The production yield % =

weight of the collected solid dispersion
× 100
Total weight of drug and carrier used

(1)

2.2.4. The Drug Content Uniformity of GM Solid Dispersion
The drug content for all GM solid dispersion was calculated by dissolving an accurate weight of
each formulation equivalent to 5 mg of GM in methanol. The methanolic solution of each formulation
was subjected to analysis using a UV spectrophotometer (Shimadzu, Kyoto, Japan) at 228 nm after
appropriate dilution [17]. The drug content for all formulation was measured through the following
equation [24]:
the actual drug content
The drug content % =
× 100
(2)
the theoretical drug content
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2.2.5. The Determination of Micromeritic Properties of GM Solid Dispersion Powders
The flow properties of solid dispersion are important in the pharmaceutical industry, especially in
the blending of powders, compression of tablets, and the filling of capsules. Several parameters were
used to measure the flow properties of the prepared solid dispersion, such as the bulk density, the
tapped density, the angle of repose, Carr’s index, and Hausner’s ratio.
The Bulk Density
The bulk density of GM solid dispersion formulations was determined by transferring an accurate
weight of each formulation (10 g) to a graduated cylindrical measure [25]. The volume of solid
dispersion was noted in the cylinder measure without any compacting, and the bulk density was
calculated by the following equation [25,26]:
Bulk density = Weight of powder/Bulk volume

(3)

The Tapped Density
The tapped density of GM solid dispersion was determined by transferring an accurate weight of
each formulation (10 g) to a graduated cylindrical measure [27]. The cylinder was tapped until no
further change in volume. The tapped density was calculated by the following equation [28]:
Tapped density = weight of powder/Tapped volume

(4)

Hausner’s Ratio
Hausner’s ratio of GM solid dispersion was determined to determine the flowability of the
formulations [10]. Hausner’s ratio was calculated by the following equation [29,30]:
Hausner ratio = Tapped density/Bulk density

(5)

Carr’s Index
Carr’s index is another parameter used to predict the flowability of powder [31]. Carr’s index of
the prepared GM solid dispersion was calculated by the following equation [32]:
Carr’ s index =

Tapped density − Bulk density
× 100
Tapped density

(6)

The Angle of Repose
The angle of repose (θ) of GM solid dispersion powders was estimated using the fixed funnel
method. An accurate weight of GM solid dispersion was allowed to pass through a fixed funnel
adjusted to 1 cm above the horizontal plane. The passed powder was allowed to form a pile where the
apex of the pile was contacted to the end of the funnel [33]. The diameter of the pile was measured,
and the angle of repose was calculated by the following equation [34]
tan θ = h/r

(7)

where h is the height of the pile, and r is the radius of the pile base.
2.2.6. The Differential Scanning Calorimetry (DSC)
The thermal behavior of the pure GM powder, different carriers used (Mannitol, PEG 6000,
and β-cyclodextrin), and the best three formulations: F3, F6, and F9 were determined using a differential
scanning calorimeter (Shimadzu, Japan). The selected formulation F3, F6, and F9 were prepared using
different carriers; Mannitol, PEG 6000, and β-cyclodextrin, respectively. These formulations were
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selected based on the highest drug: carrier ratio because it is expected that if there is any interaction
between the drug and the carrier, it will be greater in case of a higher ratio. The measurements were
done over a temperature range from 0–300 ◦ C under nitrogen purge at 30 mL/min and a scanning rate
of 10 ◦ C/min [35,36]. The reference material used in the analysis was pure Indium (In).
2.2.7. The Infrared Spectroscopy Analysis (IR)
The infrared spectroscopy of the pure GM and carriers (Mannitol, PEG 6000, and β-cyclodextrin),
F3, F6, and F9 was determined by subjecting the samples to Fourier-Transform Infrared Spectroscopy
(FT-IR) using Shimadzu 435 U-O4 IR spectrometer (Tokyo, Japan). The infrared spectroscopy was
conducted to ensure the compatibility between the formulation ingredients used in the preparation of
GM solid dispersion. Each sample was mixed with potassium bromide and mechanically compressed
into a disc [37]. The infrared spectroscopy was measured for the disc of each sample over a wavelength
scanning range of 4000 cm−1 to 400 cm−1 [38].
2.2.8. The In-Vitro Release Study of GM from Solid Dispersion
The dissolution study of GM from the prepared solid dispersion was done using an ERWEKA
dissolution tester, apparatus II (Erweka, Heusenstamm, Germany). An accurate weight of GM (2 mg)
and each solid dispersion formulation equivalent to 2 mg of GM was placed in 900 mL of phosphate
buffer (pH 6.8) [39]. The dissolution medium was kept at a temperature of 37 ± 1 ◦ C and a speed of
100 rpm. The samples were withdrawn at different time intervals (5, 10, 15, 20, 25, 30, 45, and 60 min)
and replaced with an equivalent volume of fresh medium [40]. The withdrawn samples were filtered
and analyzed spectrophotometrically using UV spectrophotometer at 228 nm [41]. The experiment
was done in triplicates, and the mean and the standard deviation were measured [40]. The percentage
of GM released was plotted against the time, and the data of drug release was kinetically treated to
determine the best mechanism of drug release [17].
2.2.9. The Selection of Optimized Formulation of GM Solid Dispersion
The formulation ingredients were optimized to determine the optimum level of X1 and X2, which
achieve the highest value of Y1 [35].
2.2.10. The scanning Electron Microscopy of the Optimized Formulation (SEM)
The morphology of the optimized formulation of GM solid dispersion was carried out using a
scanning electron microscope (JEOL, Tokyo, Japan) [42]. A dried sample of optimized formulation was
spread and adhered to aluminum stub and coated with a thin layer of platinum. The image was taken
by SEM at 30 Kv.
2.2.11. The Pharmacological Evaluation of the Antidiabetic Effect of GM Solid Dispersion
Male Wister rats (150–180 g) were obtained from the modern veterinary office for laboratory
animals (Cairo, Egypt). Groups of six rats were housed and kept under standard laboratory conditions,
with the temperature at 25 ± 1 ◦ C and relative humidity (55 ± 5%). The animals were housed in
polypropylene cages, six per cage. All experimental protocols were approved by the Research Ethics
Committee at the Faculty of Pharmacy, the British University in Egypt (No. EX-2006, Date 8 July 2020).
All animals were subjected to intraperitoneal injection with 50 mg⁄kg streptozotocin (STZ).
The blood glucose level was measured for all rats after 72 h of injection. Rats that completed the in vivo
study were selected based on the blood glucose level (>250 mg/dL) [43]. The diabetic rats were divided
into three groups, each of six rats, as follows:
Group I: control group treated with oral saline.
Group II: a diabetic group treated with free GM (0.1 mg/kg; per oral).
Group III: a diabetic group treated with F9 (0.1 mg/kg; per oral).
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After receiving the previous treatments, blood samples were collected from the tail vein at the
end of each hour for 8 h. The collected blood samples were analyzed for the blood glucose level using
a commercial glucose kit.
2.2.12. The Statistical Analysis
The results of the in vivo study were subjected to statistical analysis using one-way ANOVA
followed by Bonferroni’s post-hoc analysis. The difference was considered significant at p values <
0.05.
3. Results and Discussion
Nine formulations of GM solid dispersion were designed by 32 multilevel factorial design using
design expert software version 12. The factorial design was used to determine the effect of formulation
variables on the dissolution profile of GM.
3.1. The Production Yield % (PY%)
Nine formulations of GM solid dispersion were successfully prepared by a solvent evaporation
technique with high production yield % ranged from 98.4 ± 2.8% to 99.8 ± 2.2%, as shown in Table 3.
The results were in full agreement with Sahoo et al., who have found that the production yield % of
GM solid dispersion ranged between 96.5 ± 2.1% and 99.4 ± 1.2% [22].
Table 3. Characterization of prepared glimepiride solid dispersion formulations.
Formulation No.

PY %

DC %

F1
F2
F3
F4
F5
F6
F7
F8
F9

99.5 ± 2.5
98.5 ± 3.1
99.1 ± 1.5
98.4 ± 2.8
99.8 ± 2.2
99.2 ± 3.9
99.7 ± 2.1
98.7 ± 2.3
98.8 ± 3.7

98.1 ± 1.5
97.4 ± 2.6
99.6 ± 2.1
96.8 ± 2.9
99.3 ±3.7
97.2 ± 3.2
98.7 ± 2.7
98.3 ± 2.4
99.5 ± 1.8

3.2. The Drug Content %(DC%)
As represented in Table 3, the drug content for all formulation of GM solid dispersion was
calculated, and it was found in the range of 96.8 ± 2.9–99.6 ± 2.1%. The high value of drug content
indicated that the choice of the carriers and the method of preparation were reproducible. These
results were in accordance with Sahoo et al., who prepared the GM solid dispersion using PEG 6000,
PEG 10000, and Gelucire 44/14 and found that the drug content was in the range of 97.5 ± 1.2–99.5 ±
0.9% [22].
3.3. The Micromeritics Properties of GM Solid Dispersion
3.3.1. The Bulk and Tapped Density
The flow properties of the solid dispersion were investigated by measuring the bulk density
and tapped density. The results of bulk and tapped density were represented in Table 4. It was
found that the results of bulk and tapped density were in the range of 0.37 ± 0.05–0.54 ± 0.03 g/cm3
and 0.43 ± 0.03–0.61 ± 0.02 g/cm3 , respectively. These results were in agreement with Chavan et al.,
who prepared nisoldipine solid dispersion using a solvent evaporation technique [44].
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Table 4. The characterization of the glimepiride solid dispersion formulations concerning bulk density,
tapped density, Hausner’s ratio, Carr’s index, and angle of repose. Values were expressed in mean ±
SD (n = 3).
Formulation No.

Bulk Density
(g/cm3 )

Tapped Density
(g/cm3 )

Hausenr’s
Ratio

Carr’s Index
(%)

Angle of
Repose

F1
F2
F3
F4
F5
F6
F7
F8
F9

0.54 ± 0.03
0.46 ± 0.02
0.47 ± 0.02
0.51 ± 0.01
0.49 ± 0.03
0.45 ± 0.04
0.42 ± 0.03
0.37 ± 0.05
0.40 ± 0.04

0.61 ± 0.02
0.51 ± 0.01
0.54 ± 0.01
0.57 ± 0.01
0.58 ± 0.02
0.55 ± 0.02
0.50 ± 0.01
0.43 ± 0.02
0.48 ± 0.01

1.13 ± 0.03
1.11 ± 0.01
1.15 ± 0.02
1.12 ± 0.01
1.18 ± 0.01
1.22 ± 0.02
1.19 ± 0.02
1.16 ± 0.03
1.20 ± 0.03

11.48 ± 0.34
9.80 ± 0.54
12.96 ± 0.65
10.53 ± 0.15
15.52 ± 0.95
18.18 ± 0.47
16.00 ± 0.45
13.95 ± 0.12
16.67 ± 0.38

17.45 ± 0.82
14.26 ± 0.91
18.45 ± 0.75
15.85 ± 0.64
19.45 ± 0.54
23.44 ± 0.63
20.91 ± 0.68
18.67 ± 0.42
22.86 ± 0.46

3.3.2. Hausner’s Ratio
The value of Hausner’s ratio was found to give an indication of the flow properties of solid
dispersion. The values <1.25 indicate better flowability than values >1.25 [44]. As represented in
Table 4, Hausner’s ratio of all prepared GM solid dispersion formulations was in the range of 1.11 ± 0.01
to 1.22 ± 0.02, which indicated good flowability [45].
3.3.3. Carr’s Index (the Compressibility %)
There is an inverse relationship between the compressibility percentage and the flowability of the
solid dispersion [46]. As Carr’s index increased, the flowability decreased. The values from 5 to 12
indicate excellent flowability; the values from 12 to 16 exhibit good flowability; the values between
18 and 21 show fair passable flowability; the values ranged from 23 to 35 exhibit poor flowability;
while the values between 33 and 38 exhibit very poor flowability [23].
For all prepared GM solid dispersion formulations, the value of Carr’s index was in the range of
9.80 ± 0.54–18.18 ± 0.47%, which indicated a good flowability as represented in Table 4. The results
were in full agreement with Malviya et al., who prepared paracetamol solid dispersion [47].
3.3.4. Angle of Repose
The flowability of the solid dispersion was found to be affected by the angle of repose [48,49].
Excellent flowability was achieved when the angle of repose was less than 20◦ . A value of 20–30◦
indicates good flowability, the values between 30◦ and 34◦ exhibit passable flowability, and the values
more than 34◦ show very poor flowability [50]. From the results represented in Table 4, it was found
that all prepared GM solid dispersion exhibited angle of repose in the range of 14.26–23.44◦ which
indicated a good flowability.
3.4. The Differential Scanning Calorimetry (DSC)
The differential scanning calorimetry (DSC) thermograms of pure GM, Mannitol, PEG 6000,
β-cyclodextrin, F3, F6, and F9 were illustrated in Figure 1. It was found that the DSC thermogram of
GM showed a single endothermic peak at 212.44 ◦ C. Chaudhari et al. found that a DSC thermogram
of GM showed an endothermic peak at 213 ◦ C [21]. The DSC thermograms of Mannitol, PEG 6000,
and β-cyclodextrin showed endothermic peaks at 170.16 ◦ C, 61.96 ◦ C, and 101.53 ◦ C respectively.
These results were in agreement with Zaini et al., who reported that Mannitol had an endothermic
peak at 166.35 ◦ C [51], Febriyenti et al. prepared Gliclazide solid dispersion systems using PEG 6000
by a solvent method and found that the DSC thermogram of PEG 6000 showed an endothermic peak
at 65.14 ◦ C [52], and Arora et al. prepared atorvastatin inclusion complex using beta-cyclodextrin
and found that the DSC thermogram of beta-cyclodextrin showed a broad endothermic peak at
101.41 ◦ C [53].
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The DSC thermogram of F3, which was prepared by mannitol, showed a single endothermic peak at
The DSC thermogram of F3, which was prepared by mannitol, showed a single endothermic
166.78 ◦ C with an absence of a GM peak. The DSC thermogram of F6, which was prepared by PEG 6000,
peak at 166.78 °C with an absence of a GM ◦peak. The DSC thermogram of F6, which was prepared
showed a single endothermic peak at 60.23 C with an absence of a GM peak. The DSC thermogram
by PEG 6000, showed a single endothermic peak
at 60.23 °C with an absence of a GM peak. The DSC
of F9 showed an endothermic peak at 97.73 ◦ C with an absence of a GM peak. The disappearance of
thermogram of F9 showed an endothermic peak at 97.73 °C with an absence of a GM peak. The
the peak of GM from the thermograms of F3, F6, and F9 showed that the drug was present in a more
disappearance of the peak of GM from the thermograms of F3, F6, and F9 showed that the drug was
soluble amorphous form. These results were in full agreement with Pathak and Kaushik, who prepared
present in a more soluble amorphous form. These results were in full agreement with Pathak and
a GM solid dispersion for enhancing the solubility using PEG 6000 and observed the disappearance of
Kaushik, who prepared a GM solid dispersion for enhancing the solubility using PEG 6000 and
the endothermic peak of GM in the DSC thermogram of the prepared solid dispersion [54].
observed the disappearance of the endothermic peak of GM in the DSC thermogram of the prepared
solid dispersion [54].
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3.7. The Effect of the Formulation Factors in the In-Vitro Release (Y1)
To study the effect of independent formulation variables (X1 , and X2 ) on the in vitro release of
To study the effect of independent formulation variables (X1, and X2) on the in vitro release of
prepared GM solid dispersion, a multiple linear regression analysis was done using the Y1 equation:
prepared GM solid dispersion, a multiple linear regression analysis was done using the Y1 equation:

(8)
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Table 5. ANOVA
analysis of Y1 (% of drug released after 1 hr) for the prepared glimepiride solid
dispersion formulations.
Source
Sum of Squares DF Mean Square F-Ratio p-Value
Model

Source
Model
A-(X1)
B-(X2)
AB
A2
B2
Residual
Correlation
Total

881.07

5

Sum
A-(X1)of Squares 198.95

DF 1

B-(X2)
881.07
AB

198.95
371.15
2.53
308.43
0.0093
12.52
893.59

371.15
2.53

5
1
1
1
1
1
3
8

1
1

176.21

42.21

0.0056

Mean
Square 47.66 F-Ratio
0.0062
198.95
371.15
176.21
2.53

198.95
371.15
2.53
308.43
0.0093
4.17

88.90
0.6056

0.0025
42.21
0.4932

47.66
88.90
0.6056
73.88
0.0022

p-Value
0.0056
0.0062
0.0025
0.4932
0.0033
0.9652
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In Vitro Drug Release Kinetics
The kinetic release study was done for all GM solid dispersions to determine the release behavior.
The release data were analyzed with zero-order, first-order, second-order, and Higuchi diffusion
models. As represented in Table 6, it was found that all release data fit first-order kinetics. These results
were found to be in agreement with those obtained by Mamatha et al., who found that the release of
nevirapine from prepared solid dispersion was fitted to first-order kinetics [61]. Also, Pagadala et al.
found that the release of GM from prepared solid dispersion was fitted to first-order kinetics [62].
Table 6. The calculated correlation coefficients for the in-vitro release of glimepiride from glimepiride
solid dispersion employing different kinetic orders or systems. H-C is Hixon Crowel. B-L is baker
& lonsdal.
Correlation Coefficient (r)
Formula No.
F1
F2
F3
F4
F5
F6
F7
F8
F9
Free glimepiride

Zero

First

Second

Diffusion

H-C

B-L

0.9916
0.9910
0.9893
0.9956
0.9932
0.9902
0.9856
0.9712
0.8797
0.9922

−0.9981
−0.9971
−0.9987
−0.9975
−0.9964
−0.9970
−0.9977
−0.9927
−0.9909
−0.9930

0.9946
0.9860
0.9884
0.9951
0.9899
0.9842
0.9968
0.9918
0.8293
0.9917

0.9959
0.9927
0.9952
0.9906
0.9876
0.9933
0.9963
0.9904
0.9454
0.9868

0.9971
0.9965
0.9977
0.9968
0.9956
0.9966
0.9951
0.9879
0.9881
0.9926

0.9973
0.9964
0.9976
0.9964
0.9957
0.9965
0.9961
0.9877
0.9654
0.9722

3.8. The Selection of Optimized Formulation of GM Solid Dispersion
The independent variables were optimized using Design Expert software (version 12) to determine
the optimized formulation. The optimized formula was selected based on the highest drug release (Q1hr ),
which achieved the highest drug release. From the results, F9 was selected as the optimized formulation.
3.9. The Scanning Electron Microscopy of the Optimized Formulation (SEM)
The surface morphology of the optimized GM solid dispersion was shown in Figure 5. It was
found that the optimized formulation appeared as irregular particles, which may give an indication of
the dispersion of GM on the carriers in an amorphous state.
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3.10. Antidiabetic Effect of GM Solid Dispersion
The antidiabetic effect of F9 was studied in comparison with free GM in STZ (Streptozotocin)
diabetic rats. As shown in Figure 6, it was found that F9 showed a high and rapid reduction in blood
glucose levels in diabetic rats, which indicated the success of the solid dispersion technique in
improving the solubility and hence the bioavailability of GM. It was found that F9 showed a
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Figure 6. The antidiabetic activity of F9 in comparison with free glimepiride. Data were analyzed

Figure 6. The antidiabetic activity of F9 in comparison with free glimepiride. Data were analyzed
statistically using one-way ANOVA followed by Bonferroni’s post-hoc test at p < 0.05. * Versus control
statistically
using one-way ANOVA followed by Bonferroni’s post-hoc test at p < 0.05. * Versus control
$ versus free glimepiride, n = 6.
and
and $ versus free glimepiride, n = 6.

4. Conclusions
The solid dispersion technique was found to be useful in improving the dissolution rate of GM.
The type, nature, and the ratio of the carrier used played an important role in the enhancement of the
dissolution rate and hence the bioavailability of GM. It was concluded that all prepared formulations
have high production yield ranged from 98.4 ± 2.8% to 99.8 ± 2.2% and high drug content in the
range of 97.2 ± 3.2% to 99.6 ± 2.1%. The micromeritic properties of all prepared GM formulations
showed a high flowability. The authors concluded that the used carriers were arranged according to
the enhancement of solubility as follows: β-cyclodextrin > Mannitol > PEG 6000. Also, increasing
the drug-carrier ratio from 1:1 to 1:6 caused an increase in the rate of GM release. The formulation
of GM as a solid dispersion formulation is a potential way to improve its solubility and enhance its
hypoglycemic effect.
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